Does Blue Cross Blue Shield Cover Evenity (Romosozumab)?

How BCBS Federated Plans Classify Evenity

Blue Cross Blue Shield is not a single insurer. It operates as a federation of 34 independent companies, each setting its own formulary and medical policy. Coverage for romosozumab therefore varies by state affiliate, plan type (HMO, PPO, EPO), and employer group. The common thread: nearly every BCBS entity that covers Evenity classifies it as a specialty biologic requiring prior authorization.

Romosozumab received FDA approval in April 2019 for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture or multiple risk factors, or patients who have failed or are intolerant to other available osteoporosis therapies. The Endocrine Society's 2020 clinical practice guideline recommends anabolic-first strategies including romosozumab for patients with very high fracture risk, which has influenced payer coverage criteria nationwide [1, 2].

Because BCBS affiliates follow independent pharmacy and therapeutics committees, a patient in Illinois may face different step-therapy requirements than one in Texas. The Federal Employee Program (FEP) Blue Cross Blue Shield plan, which covers roughly 5.3 million federal employees and dependents, publishes its own formulary separate from state-level BCBS plans. FEP generally places Evenity on the specialty tier with mandatory prior authorization [3].

Patients should verify coverage by calling the member services number on their BCBS card, or by asking their prescribing endocrinologist or rheumatologist to run a benefit investigation through the pharmacy benefit manager.

Prior Authorization Criteria for Romosozumab on BCBS

Prior authorization is the single biggest barrier to Evenity access. Approval criteria align closely with the drug's FDA label and the American Association of Clinical Endocrinology (AACE) 2020 guidelines for postmenopausal osteoporosis [4].

Most BCBS affiliates require documentation of all of the following before approving romosozumab:

1. Confirmed postmenopausal status in female patients.
2. Bone mineral density T-score of <-2.5 at the lumbar spine, femoral neck, or total hip by DXA, or a history of osteoporotic fracture (vertebral or hip) [5].
3. High fracture risk per FRAX score or clinical judgment. Many plans use a 10-year major osteoporotic fracture probability exceeding 20% or a hip fracture probability exceeding 3%, consistent with National Osteoporosis Foundation thresholds [6].
4. Trial and failure (or intolerance) of at least one antiresorptive agent, typically oral alendronate or risedronate for a minimum of 12 months, or denosumab for at least 6 months.
5. No contraindications, including no history of myocardial infarction or stroke within the prior year, per the FDA boxed warning based on cardiovascular signal data from the ARCH trial [7].

Prescribers submit the prior authorization request with supporting DXA reports, FRAX calculations, fracture imaging, and medication history. Turnaround times range from 48 hours to two weeks depending on the BCBS affiliate. Some plans use electronic prior authorization (ePA), which can return a decision within hours.

Step Therapy Requirements on BCBS Plans

Step therapy (or "fail-first" protocols) require that a patient try and fail a less expensive osteoporosis treatment before the insurer authorizes Evenity. This is standard across most BCBS federated plans.

The typical step-therapy sequence involves at least 12 months on an oral bisphosphonate such as alendronate (generic, roughly $15 per month) or risedronate. Some plans accept denosumab (Prolia) as the step-therapy agent, particularly if the patient cannot tolerate oral bisphosphonates due to esophageal disorders or GI side effects [8]. A 2016 Cochrane review confirmed bisphosphonate efficacy for fracture reduction, which supports their use as first-line agents from a payer perspective [9].

Exceptions exist. Patients with a recent hip or vertebral fracture (within 24 months) may qualify for step-therapy override, because AACE guidelines and the Endocrine Society both recommend anabolic-first therapy for very-high-risk patients [2, 4]. The rationale comes from evidence like the VERO trial (N=436), which showed teriparatide reduced new vertebral fractures by 56% compared with risedronate in high-risk postmenopausal women, establishing the principle that anabolic agents provide faster fracture protection than antiresorptives alone [10].

If your prescriber believes step therapy should be bypassed, they can submit a step-therapy exception request documenting imminent fracture risk or prior treatment failure.

What Formulary Tier Is Evenity on BCBS Plans?

Evenity is a biologic administered as two subcutaneous injections (each 105 mg/1.17 mL) once monthly in a healthcare setting. This delivery model places it on the specialty tier of most BCBS formularies, typically Tier 4 or Tier 5.

Specialty-tier cost-sharing varies widely. Some BCBS plans charge a flat specialty copay of $100 to $250 per fill. Others apply coinsurance of 20% to 40%, which against the $1,825 list price yields an out-of-pocket cost of $365 to $730 per month before any manufacturer assistance. The total 12-month course at list price runs approximately $21,900 [11].

The ARCH trial (N=4,093) provides the clinical value argument for this cost: romosozumab for 12 months followed by alendronate reduced new vertebral fractures by 48% and hip fractures by 38% compared with alendronate alone at 24 months [7]. A 2020 cost-effectiveness analysis published in JBMR estimated that romosozumab followed by alendronate was cost-effective at a willingness-to-pay threshold of $150,000 per quality-adjusted life year in women aged 70 and older with T-scores of <-2.5 and prior fracture [12].

Patients enrolled in BCBS plans with high coinsurance should ask about Amgen's Evenity copay assistance program, which may reduce costs to as low as $5 per month for eligible commercially insured patients. Copay cards do not apply to government-funded insurance, including Medicare, Medicaid, or Tricare.

How to Appeal a BCBS Denial for Evenity

Denials happen. A 2021 survey of specialty pharmacy prior authorization data indicated that roughly 20% to 30% of initial biologic prior authorization requests are denied before appeal. BCBS plans offer a structured appeals process.

Step 1: Internal appeal. Within 180 days of denial, submit a written appeal to your BCBS plan. Include a letter of medical necessity from the prescribing physician, updated DXA results, FRAX score, fracture history documentation, imaging, and records of failed prior therapies. Reference the Endocrine Society guideline and AACE guideline recommendations for anabolic-first therapy in very-high-risk patients [2, 4].

Step 2: Peer-to-peer review. Request a physician-to-physician call between your prescriber and the BCBS medical director reviewing the case. This is often the most effective step. The prescriber can explain why the patient meets criteria and why delay increases fracture risk. Data from the FRAME trial (N=7,180) showing that romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months can strengthen the clinical argument [13].

Step 3: External review. If the internal appeal is denied, BCBS members in most states have the right to an independent external review by a third-party organization. State insurance departments oversee this process. The external reviewer's decision is typically binding on the insurer.

Step 4: State insurance department complaint. If you believe the denial violates your plan's stated coverage policy or state parity laws, file a complaint with your state's department of insurance.

For FEP BCBS members, the appeals process follows the Office of Personnel Management (OPM) guidelines for federal employee health benefits, which includes a disputed-claims process and access to OPM review [14].

Throughout the appeal, specificity matters. Cite the patient's exact T-score, the exact fracture site and date, the exact prior therapy name and duration, and the exact guideline recommendation. Vague statements like "high fracture risk" are less persuasive than "T-score of -3.2 at the femoral neck with a 10-year FRAX hip fracture probability of 8.4%, status post L1 compression fracture in March 2025."

Manufacturer Savings and Financial Assistance

Amgen offers the Evenity copay card program for commercially insured patients, potentially covering all but $5 of the monthly out-of-pocket cost, up to an annual maximum benefit. Eligibility typically requires commercial insurance (including BCBS plans) and excludes patients covered under any federal or state healthcare program [15].

For patients without insurance or with coverage gaps, Amgen's patient assistance program may provide Evenity at no cost for qualifying individuals with household incomes below 300% of the federal poverty level. Applications go through the Amgen Safety Net Foundation.

Specialty pharmacies dispensing Evenity often have financial counselors who can help patients understand their BCBS benefit structure and identify the lowest out-of-pocket pathway. Ask your prescriber's office for a referral to the specialty pharmacy's financial navigation team.

An additional consideration: some BCBS plans cover Evenity under the medical benefit (since it is administered by a healthcare provider) rather than the pharmacy benefit. When coverage falls under the medical benefit, cost-sharing may follow the plan's outpatient procedure coinsurance rather than the pharmacy tier structure. This distinction can significantly affect out-of-pocket costs, so confirm which benefit applies with your BCBS plan [16].

Cardiovascular Safety and the BCBS Approval Lens

The FDA boxed warning on Evenity highlights an increased risk of myocardial infarction, stroke, and cardiovascular death observed in the ARCH trial [7]. In that study, major adverse cardiovascular events occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients during the 12-month active-treatment phase [7].

This safety signal directly affects BCBS coverage criteria. Most BCBS affiliates include a cardiovascular screening requirement in their prior authorization criteria, denying coverage for patients with MI or stroke in the preceding 12 months. Some plans extend this exclusion to patients with multiple cardiovascular risk factors even absent a recent event.

A post-hoc analysis of the FRAME trial found no excess cardiovascular risk with romosozumab versus placebo, suggesting the ARCH signal may relate to a cardioprotective effect of the alendronate comparator rather than a harmful effect of romosozumab itself [17]. The 2022 European Medicines Agency assessment reached a similar conclusion but maintained the cardiovascular warning as a precaution [18]. Prescribers can reference these analyses in prior authorization submissions when BCBS plans flag cardiovascular concerns for patients at low baseline cardiovascular risk.

Sequencing Therapy After the 12-Month Romosozumab Course

Evenity's FDA label limits treatment to 12 monthly doses. This is not a limitation insurers impose. The bone-forming effect of sclerostin inhibition wanes after 12 months as anti-drug antibodies and physiologic feedback reduce the anabolic signal. The ARCH trial protocol transitioned all patients to alendronate after the romosozumab or comparator phase, and the fracture-reduction benefit persisted through month 24 [7].

BCBS plans expect a documented transition plan in the prior authorization submission. Standard post-romosozumab sequencing supported by AACE and Endocrine Society guidelines includes oral alendronate or zoledronic acid (annual IV infusion) to consolidate the gains from the anabolic phase [2, 4]. Denosumab is an alternative, though prescribers must plan for the rebound bone loss risk if denosumab is later discontinued, as documented in a 2017 JBMR study showing rapid BMD loss and vertebral fracture clusters after denosumab cessation [19].

Some BCBS plans will not re-authorize a second 12-month course of romosozumab, as no long-term repeat-dosing trial data exist. Patients needing additional anabolic therapy after romosozumab completion may be considered for teriparatide (Forteo) or abaloparatide (Tymlos), each requiring its own prior authorization [20].

The most effective sequence for BCBS prior authorization success: document the full treatment arc from romosozumab (12 months) to a named antiresorptive (ongoing), demonstrating to the payer that the prescriber has a defined clinical endpoint and is not requesting open-ended biologic therapy.